<!DOCTYPE html>
<html>
<head>
    <title>PressReader - The Straits Times: 2020-10-08 - NCID to en&#xAD;rol Covid-19 pa&#xAD;tients for in&#xAD;ter&#xAD;na&#xAD;tional an&#xAD;ti&#xAD;body trial</title>
    <meta name="description" content="Ear&#xAD;lier tri&#xAD;als of an&#xAD;ti&#xAD;body de&#xAD;vel&#xAD;oped by US firm show it is safe, im&#xAD;proves symp&#xAD;toms">
    <meta content="magazines, newspapers, digital news, reading, news, breaking news, newspaper online" name="keywords">
    <meta name="Robots" content="NOARCHIVE,NOODP">
    <meta charset="UTF-8">
    <meta http-equiv="Content-type" content="text/html; charset=utf-8" />
    <meta name="viewport" content="width=device-width, initial-scale=1" />
    
    <link rel="canonical" href="/singapore/the-straits-times/20201008/281809991358588" />


    <style>
        li {
            margin: 1em 0;
        }
        img {
            max-width: 100%;
        }
        p, h1, h2, h3 {
            max-width: 100%;
        }
    </style>
</head>
<body>
    <div>
        

<article>
    <h1>NCID to en&#xAD;rol Covid-19 pa&#xAD;tients for in&#xAD;ter&#xAD;na&#xAD;tional an&#xAD;ti&#xAD;body trial</h1>
    <h2>Ear&#xAD;lier tri&#xAD;als of an&#xAD;ti&#xAD;body de&#xAD;vel&#xAD;oped by US firm show it is safe, im&#xAD;proves symp&#xAD;toms</h2>
    <section>
        <a href="/singapore/the-straits-times/textview" title="The Straits Times">The Straits Times</a>
        - <a href="/singapore/the-straits-times/20201008/textview" title="The Straits Times - 2020-10-08"><time>2020-10-08</time></a>
        - <span>TOP OF THE NEWS</span>
        - <span role="byline">Clara Chong and Sha&#xAD;bana Begum chongcjy@sph.com.sg nshab@sph.com.sg</span>
    </section>

    <p>Covid-19 pa­tients in Sin­ga­pore will be in­volved in an in­ter­na­tional trial to test an an­ti­body treat­ment for the coro­n­avirus in­fec­tion.</p>
    <p>The Na­tional Cen­tre for In­fec­tious Dis­eases (NCID) said in a state­ment yes­ter­day that it is ready to en­rol the first pa­tients for the mon­o­clonal an­ti­body treat­ment trial. It did not in­di­cate how many will be in­volved in the trial or when they will join the trial.</p>
    <p>A mon­o­clonal an­ti­body is a pu­ri­fied, highly ac­tive an­ti­body that tar­gets the spike pro­tein of the coro­n­avirus.</p>
    <p>“Large-scale ran­domised con­trolled tri­als have proved the ef­fec­tive­ness of remde­sivir and dex­am­etha­sone in hos­pi­talised pa­tients with se­vere Covid-19,” said As­so­ciate Pro­fes­sor David Lye, senior con­sul­tant and di­rec­tor of NCID’s in­fec­tious dis­ease re­search and train­ing of­fice.</p>
    <p>“We clearly need more ef­fec­tive treat­ment op­tions. Mon­o­clonal an­ti­bod­ies are the next promis­ing phase of Covid-19 treat­ment tri­als.”</p>
    <p>Pa­tients on the trial will get ei­ther the an­ti­body or a placebo, along with the an­tivi­ral drug remde­sivir.</p>
    <p>They may also be given dex­am­etha­sone – an­other proven treat­ment – if the doc­tor deems it suit­able, he said.</p>
    <p>NCID said it will fo­cus on treat­ing pa­tients with pneu­mo­nia and a smaller group who needs oxy­gen.</p>
    <p>The mon­o­clonal an­ti­body was de­vel­oped by Amer­i­can phar­ma­ceu­ti­cal com­pany Eli Lilly. Phase one tri­als have shown that it is safe and can im­prove pa­tients’ symp­toms and re­duce their vi­ral load.</p>
    <p>Named Ac­tiv-3, the trial which started in Au­gust has re­cruited over 200 Covid-19 pa­tients, mainly from the United States and Den­mark.</p>
    <p>On Tues­day, The Straits Times re­ported that one of the two an­ti­bod­ies in the cock­tail used to treat US Pres­i­dent Don­ald Trump for Covid-19 was de­vel­oped us­ing blood sam­ples from three pa­tients in Sin­ga­pore.</p>
    <p>NCID has yet to com­ment on whether its cur­rent trial is linked to the ear­lier de­vel­op­ment.</p>

    <div>
        <picture>
            <img src="https://i.prcdn.co/img?regionKey=FyjfPCbd2PNczeaFRlpr6Q%3d%3d" />
        </picture>
        <span role="byline">ST PHOTO:&#xD;&#xA;KUA CHEE SIONG</span>
        <p data-role="text">The Na&#xAD;tional Cen&#xAD;tre for In&#xAD;fec&#xAD;tious Dis&#xAD;eases is ready to en&#xAD;rol the first pa&#xAD;tients for the mon&#xAD;o&#xAD;clonal an&#xAD;ti&#xAD;body treat&#xAD;ment trial. It will fo&#xAD;cus on treat&#xAD;ing pa&#xAD;tients with pneu&#xAD;mo&#xAD;nia and a smaller group who needs oxy&#xAD;gen.</p>
    </div>

</article>

<section>
    <h3><a href="/catalog/language/english">Newspapers in English</a></h3>
    <h3><a href="/catalog/country/singapore">Newspapers from Singapore</a></h3>
</section>

    </div>
    
    <p><a href="http://www.pressreader.com">© PressReader. All rights reserved.</a></p>

        <script>
            (function (i, s, o, g, r, a, m) {
                i['GoogleAnalyticsObject'] = r; i[r] = i[r] || function () {
                    (i[r].q = i[r].q || []).push(arguments);
                }, i[r].l = 1 * new Date();
                a = s.createElement(o), m = s.getElementsByTagName(o)[0]; a.async = 1; a.src = g;
                m.parentNode.insertBefore(a, m);
            })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
        </script>
        <script>
            ga('create', 'UA-44408245-1');
            ga('send', 'pageView');
        </script>
</body>
</html>
